United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. aromasin is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, aromasin can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fetal toxicit

Israel - English - Ministry of Health

abic marketing ltd, israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

Israel - English - Ministry of Health

abic marketing ltd, israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: purified talc; microcrystalline cellulose; colloidal anhydrous silica; acacia; mannitol; polysorbate 80; magnesium stearate; sucrose; titanium dioxide; crospovidone; ethanol; shellac; white beeswax; carnauba wax - sequential adjuvant treatment of oestrogen receptor positive early breast cancer in postmenopausal women who have received prior adjuvant tamoxifen therapy.,treatment of oestrogen receptor positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following antioestrogen therapy.

United States - English - NLM (National Library of Medicine)

alvogen inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies ( 14.1 )] . exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies ( 14.2 )] . exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abo

United States - English - NLM (National Library of Medicine)

a-s medication solutions - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies ( 14.1 )] . exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies ( 14.2 )] . exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abo

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - exemestane - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

beacon pharmaceuticals ltd - exemestane - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - exemestane - oral tablet - 25mg